About   Help   FAQ
Mammalian Phenotype Ontology Annotations
Query Results - Summary
Symbol
Name
ID 		Ppargc1a
peroxisome proliferative activated receptor, gamma, coactivator 1 alpha
MGI:1342774
142 phenotypes from 11 alleles in 19 genetic backgrounds
Export: Excel File
Allelic Composition
Genetic Background		 Annotated Term Reference
Ppargc1aem1(IMPC)Bay/Ppargc1a+
C57BL/6N-Ppargc1aem1(IMPC)Bay/BayMmucd 		increased startle reflex J:211773
Ppargc1aem1(IMPC)Bay/Ppargc1aem1(IMPC)Bay
C57BL/6N-Ppargc1aem1(IMPC)Bay/BayMmucd 		preweaning lethality, incomplete penetrance J:211773
Ppargc1atm1.1Amos/Ppargc1atm1.1Amos
involves: C57BL/6JOlaHsd 		abnormal crypts of Lieberkuhn morphology J:171361
abnormal small intestinal villus morphology J:171361
increased incidence of tumors by chemical induction J:171361
increased tumor growth/size J:171361
Ppargc1atm1.1Javi/Ppargc1atm1.1Javi
Tg(Fabp4-cre)1Rev/0
B6.Cg-Ppargc1atm1.1Javi Tg(Fabp4-cre)1Rev 		abnormal brown fat cell morphology J:180984
normal adipose tissue phenotype J:180984
decreased body weight J:180984
decreased brown fat cell size J:180984
decreased liver weight J:180984
decreased total body fat amount J:180984
decreased white fat cell size J:180984
Ppargc1atm1Aztc/Ppargc1a+
C57BL/6-Ppargc1atm1Aztc 		decreased body length J:82809
decreased body weight J:82809
decreased bone mineral content J:82809
decreased circulating cholesterol level J:82809
decreased food intake J:82809
decreased lean body mass J:82809
decreased respiratory quotient J:82809
decreased retroperitoneal fat pad weight J:82809
increased adrenal gland weight J:82809
increased circulating alkaline phosphatase level J:82809
increased kidney weight J:82809
increased thymus weight J:82809
thrombocytopenia J:82809
Ppargc1atm1Aztc/Ppargc1atm1Aztc
C57BL/6-Ppargc1atm1Aztc 		decreased body fat mass J:82809
decreased body weight J:82809
decreased circulating glucose level J:82809
decreased circulating insulin level J:82809
decreased lean body mass J:82809
Ppargc1atm1Brsp/Ppargc1a+
involves: 129 * FVB/N 		normal immune system phenotype J:127403
Ppargc1atm1Brsp/Ppargc1a+
involves: 129S4/SvJae * C57BL/6 		abnormal Bruch membrane morphology J:264271
abnormal choriocapillaris morphology J:264271
abnormal choroid vasculature morphology J:264271
abnormal melanosome transport J:264271
abnormal mitochondrial physiology J:264271
abnormal retina pigment epithelium morphology J:264271
decreased mitochondrial DNA content J:264271
impaired autophagy J:264271
increased inflammatory response J:264271
lipofuscinosis J:264271
oxidative stress J:264271
retina macular degeneration J:264271
retina photoreceptor degeneration J:264271
short photoreceptor inner segment J:264271
short photoreceptor outer segment J:264271
Ppargc1atm1Brsp/Ppargc1atm1Brsp
involves: 129 * FVB/N 		cachexia J:111072
congestive heart failure J:111072
increased heart weight J:111072
increased interleukin-6 secretion J:127403
increased lung weight J:111072
increased response of heart to induced stress J:111072
Ppargc1atm1Brsp/Ppargc1atm1Brsp
involves: 129/Sv * C57BL/6 * FVB/N 		abnormal brown adipose tissue morphology J:93896
abnormal cellular respiration J:93896
abnormal gluconeogenesis J:93896
abnormal glucose homeostasis J:93896
abnormal lipid homeostasis J:93896
abnormal neuron morphology J:93896
anhedonia J:213551
decreased circulating insulin level J:93896
decreased liver triglyceride level J:93896
decreased susceptibility to diet-induced obesity J:93896
dystonia J:93896
gliosis J:93896
hyperactivity J:93896
hypoglycemia J:93896
impaired adaptive thermogenesis J:93896
improved glucose tolerance J:93896
increased insulin sensitivity J:93896
increased oxygen consumption J:93896
increased startle reflex J:93896
increased susceptibility to induced morbidity/mortality J:93896
limb grasping J:93896
myoclonus J:93896
postnatal lethality, incomplete penetrance J:93896
spongiform encephalopathy J:93896
Ppargc1atm1Brsp/Ppargc1atm2Brsp
Tg(Myog-cre)1Eno/0
involves: 129 * C57BL/6 * FVB/N 		abnormal glucose homeostasis J:127403
abnormal mitochondrial physiology J:127403
abnormal pancreatic beta cell morphology J:127403
decreased body weight J:127403
decreased circulating insulin level J:127403
decreased food intake J:127403
decreased percent body fat/body weight J:127403
decreased respiratory quotient J:127403
decreased susceptibility to diet-induced obesity J:127403
normal endocrine/exocrine gland phenotype J:127403
enlarged pancreatic islets J:127403
normal homeostasis/metabolism phenotype J:127403
hyperglycemia J:127403
impaired glucose tolerance J:127403
increased basal metabolism J:127403
increased circulating glucose level J:127403
increased circulating interleukin-6 level J:127403
increased oxygen consumption J:127403
increased pancreatic beta cell mass J:127403
Ppargc1atm1Dpk/Ppargc1atm1Dpk
B6.129X1-Ppargc1atm1Dpk/J 		abnormal substantia nigra morphology J:298664
bradykinesia J:298664
decreased locomotor activity J:298664
decreased nervous system dopamine level J:298664
impaired coordination J:298664
neurodegeneration J:298664
Ppargc1atm1Dpk/Ppargc1atm1Dpk
involves: 129X1/SvJ 		abnormal blood circulation J:137598
abnormal brown adipose tissue morphology J:137598
abnormal fat cell morphology J:137598
decreased triglyceride level J:137598
Ppargc1atm1Dpk/Ppargc1atm1Dpk
involves: 129X1/SvJ * C57BL/6 		abnormal basal ganglion morphology J:96306
abnormal body weight J:96306
abnormal brainstem morphology J:96306
abnormal cellular respiration J:96306
abnormal cerebellum morphology J:96306
abnormal cerebral cortex morphology J:96306
abnormal hippocampus morphology J:96306
abnormal liver physiology J:96306
abnormal locomotor behavior J:96306
abnormal skeletal muscle fiber morphology J:96306
decreased cardiac output J:96306
decreased gastrocnemius weight J:96306
decreased grip strength J:96306
decreased heart rate J:96306
decreased heart weight J:96306
decreased oxygen consumption J:96306
decreased skeletal muscle weight J:96306
decreased soleus weight J:96306
decreased ventricle muscle contractility J:96306
fatigue J:96306
hepatic steatosis J:96306
impaired adaptive thermogenesis J:96306
improved glucose tolerance J:96306
increased insulin sensitivity J:96306
increased muscle fatigability J:96306
increased percent body fat/body weight J:96306
increased susceptibility to weight gain J:96306
increased thigmotaxis J:96306
increased total body fat amount J:96306
Ppargc1atm2.1Brsp/Ppargc1atm2.1Brsp
involves: 129 		abnormal behavioral response to amphetamine J:234906
decreased dopamine level J:234906
decreased dopaminergic neuron number J:234906
Ppargc1atm2.1Brsp/Ppargc1atm2.1Brsp
Tg(Myog-cre)1Eno/0
involves: 129 * BALB/c * C57BL/6J * C57BL/6N 		abnormal mitochondrial physiology J:208380
decreased circulating glucose level J:208380
decreased circulating insulin level J:208380
decreased lean body mass J:208380
decreased respiratory quotient J:208380
normal growth/size/body region phenotype J:208380
impaired glucose tolerance J:208380
increased percent body fat/body weight J:208380
insulin resistance J:208380
Ppargc1atm2Brsp/Ppargc1a+
Tg(Myog-cre)1Eno/0
involves: 129 * C57BL/6 		normal behavior/neurological phenotype J:127403
normal growth/size/body region phenotype J:127403
normal homeostasis/metabolism phenotype J:127403
impaired glucose tolerance J:127403
increased circulating glucose level J:127403
increased circulating interleukin-6 level J:127403
Ppargc1atm2Brsp/Ppargc1atm2Brsp
involves: 129 		male infertility J:127403
Ppargc1atm2Brsp/Ppargc1atm2Brsp
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
involves: 129 * C57BL/6 * DBA 		abnormal blood homeostasis J:115197
abnormal cell physiology J:115197
Tg(Ckm-Ppargc1a)31Brsp/0
C57BL/6-Tg(Ckm-Ppargc1a)31Brsp 		abnormal depression-related behavior J:213551
abnormal muscle physiology J:78333
abnormal skeletal muscle morphology J:78333
Tg(Ckm-Ppargc1a)31Brsp/0
C57BL/6-Tg(Ckm-Ppargc1a)31Brsp/J 		abnormal aerobic respiration J:176080
increased mitochondrial fission J:176080
Tg(Myh6-rtTA)8585Jam/0
Tg(tetO-Ppargc1a)1Dpk/0
involves: FVB/N * FVB/NTac 		abnormal heart left ventricle morphology J:96614
abnormal mitochondrial morphology J:96614
abnormal myocardial fiber morphology J:96614
cardiac hypertrophy J:96614
cardiomyopathy J:96614
decreased cardiac muscle contractility J:96614
decreased heart rate J:96614
dilated heart left ventricle J:96614
dilated heart right ventricle J:96614
increased heart rate J:96614
increased mitochondrial fission J:96614
Tg(Myog-Ppargc1a_i4)#Brsp/0
Not Specified 		decreased body fat mass J:211329
decreased epididymal fat pad weight J:211329
decreased subcutaneous adipose tissue amount J:211329
decreased susceptibility to diet-induced obesity J:211329
Contributing Projects:
Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Models of Human Cancer database (MMHCdb) (formerly Mouse Tumor Biology (MTB)), Gene Ontology (GO)
Citing These Resources
Funding Information
Warranty Disclaimer, Privacy Notice, Licensing, & Copyright
Send questions and comments to User Support. 		last database update
04/16/2024
MGI 6.23 		The Jackson Laboratory